CellaVision Management

Management criteria checks 2/4

CellaVision's CEO is Simon Ostergaard, appointed in Mar 2021, has a tenure of 3.08 years. directly owns 0.021% of the company’s shares, worth €97.07K. The average tenure of the management team and the board of directors is 3.2 years and 3.3 years respectively.

Key information

Simon Ostergaard

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	3.1yrs
CEO ownership	0.02%
Management average tenure	3.2yrs
Board average tenure	3.3yrs

Recent management updates

Recent updates

CEO

Simon Ostergaard (52 yo)

3.1yrs

Tenure

Mr. Simon Ostergaard has been the Chief Executive Officer and President at CellaVision AB (publ) since March 21, 2021. He has broad experience is primarily in CellaVision's adjacent area of pathology and o...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Christer Fahraeus	Founder & Director	no data	kr285.00k	7.25% SEK 33.6m
Simon Ostergaard	CEO & President	3.1yrs	no data	0.021% SEK 97.1k
Magnus Blixt	Chief Financial Officer	10.9yrs	no data	0.017% SEK 77.7k
Adele Horn	Corporate Communications & Investor Relations Manager	no data	no data	no data
Peter Wilson	Vice President of Global Marketing	no data	no data	0.013% SEK 58.3k
Urban Strindlov	Vice President of Global Sales	2.3yrs	no data	no data
Nina Wallander	Vice President of Human Resources	3.3yrs	no data	no data

3.2yrs

Average Tenure

56.5yo

Average Age

Experienced Management: C26's management team is considered experienced (3.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Christer Fahraeus	Founder & Director	30.3yrs	kr285.00k	7.25% SEK 33.6m
Mikael Worning	Independent Chairman of the Board	4.3yrs	kr800.00k	0.0099% SEK 45.8k
Stefan Wolf	Independent Director	5.9yrs	kr260.00k	no data
Ann-Charlotte Jarleryd	Independent Director	1.9yrs	kr360.00k	no data
Kent Strahlen	Independent Employee Representative Director	2.3yrs	no data	0.0042% SEK 19.4k
Louise Armstrong-Denby	Independent Director	less than a year	kr130.00k	no data

3.3yrs

Average Tenure

57.5yo

Average Age

Experienced Board: C26's board of directors are considered experienced (3.3 years average tenure).

CellaVision Management

Management criteria checks 2/4

Key information

Recent management updates

CellaVision AB (publ) Announces the Appointment of Emil Hjalmarsson as Chairman of the Nomination Committee

Founder & Director recently sold €1.1m worth of stock

CellaVision Announces Executive Changes

Sören Mellstig Not Stands for Re-election as Chairman of the Board of CellaVision AB

Recent updates

First quarter 2024 earnings released: EPS: kr1.26 (vs kr0.81 in 1Q 2023)

Full year 2023 earnings released: EPS: kr5.46 (vs kr4.96 in FY 2022)

Now 20% undervalued

Now 21% undervalued

Dividend of kr2.25 announced

Full year 2023 earnings released: EPS: kr5.46 (vs kr4.96 in FY 2022)

Investor sentiment improves as stock rises 32%

Now 25% undervalued

Now 22% undervalued after recent price drop

Investor sentiment improves as stock rises 18%

Third quarter 2023 earnings released: EPS: kr1.09 (vs kr0.43 in 3Q 2022)

CellaVision AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

CellaVision AB (publ) to Report Q3, 2023 Results on Oct 25, 2023

Now 20% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: kr1.46 (vs kr1.56 in 2Q 2022)

CellaVision AB (publ) to Report Q2, 2023 Results on Jul 20, 2023

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 19%

Cellavision AB (Publ) Approves Dividend, Payable on May 12, 2023

Upcoming dividend of kr2.25 per share at 1.3% yield

Investor sentiment improves as stock rises 15%

Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021)

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021)

Now 24% undervalued after recent price drop

Cellavision AB (Publ) Proposes Dividend for 2022

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

CellaVision AB (publ) Announces the Appointment of Emil Hjalmarsson as Chairman of the Nomination Committee

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: EPS: kr0.43 (vs kr1.09 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

CellaVision® Launches a Complete Workflow Solution for Low-Volume Hematology Laboratories

Second quarter 2022 earnings released: EPS: kr1.56 (vs kr1.30 in 2Q 2021)

Cellavision AB (Publ) Announces Dividend, Payable on 18 May 2022

First quarter 2022 earnings released: EPS: kr1.61 (vs kr1.19 in 1Q 2021)

Upcoming dividend of kr2.00 per share

Full year 2021 earnings released: EPS: kr5.26 (vs kr3.75 in FY 2020)

Investor sentiment improved over the past week

Cellavision AB (Publ) Proposes Dividend for 2021

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS kr1.09 (vs kr0.56 in 3Q 2020)

Founder & Director recently sold €1.1m worth of stock

Second quarter 2021 earnings released: EPS kr1.30 (vs kr1.14 in 2Q 2020)

Independent Chairman of the Board Sören Mellstig has left the company

CellaVision AB (publ) Approves Dividend, Payable on 6 May 2021

Upcoming dividend of kr0.75 per share

Full year 2020 earnings released: EPS kr3.75 (vs kr4.16 in FY 2019)

Revenue misses expectations

Full year 2020 earnings released: EPS kr3.75 (vs kr4.16 in FY 2019)

New 90-day high: €32.02

CellaVision Announces Executive Changes

New 90-day low: €27.24

Market pulls back on stock over the past week

Sören Mellstig Not Stands for Re-election as Chairman of the Board of CellaVision AB

New 90-day high: €33.86

New 90-day high - €30.56

New 90-day high - €29.80

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age